Table 2-2.

The clinical outcomes during the 30 days of follow-up period.

	Probiotic group (n = 47)	Control group (n = 50)	P -value
Incidence of respiratory tract infections	0	6/50 (12.00%)	0.025
Respiratory symptoms onset (days)	0	23
Sick days (days/person)	0	0.46 ± 1.43	0.027
Duration of each episode (days/episode)	0	4.20 ± 1.64	0.027
Absence from school (days/person)	0	0.46 ± 1.29	0.014
Absence from work (days/person)	0	0.30 ± 0.90	0.025
Taking antibiotics (days/person)	0	0.16 ± 0.81	0.164
Taking anti-viral drug (days/person)	0	0.14 ± 0.70	0.164
Taking antipyretics drug (days/person)	0	0.06 ± 0.42	0.327